Show Search Form
registered interest | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
date | |||||||||||||||||||||||||||||||
answering body |
|
||||||||||||||||||||||||||||||
answering dept id | 17 | ||||||||||||||||||||||||||||||
answering dept short name | Health | ||||||||||||||||||||||||||||||
answering dept sort name | Health | ||||||||||||||||||||||||||||||
hansard heading | Cancer: Mortality Rates | ||||||||||||||||||||||||||||||
house id | 2 | ||||||||||||||||||||||||||||||
legislature |
|
||||||||||||||||||||||||||||||
question text | Her Majesty's Government what is their assessment of the findings by Integrating the Healthcare Enterprise in its report, Comparator report on patient access to cancer medicines in Europe Revisited, that UK five-year survival outcomes for cancer lag behind the European average for nine out of ten cancers. | ||||||||||||||||||||||||||||||
tabling member printed |
|
||||||||||||||||||||||||||||||
uin | HL1056 | ||||||||||||||||||||||||||||||
answer |
|
||||||||||||||||||||||||||||||
tabling member |
|
registered interest | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
date | |||||||||||||||||||||||||||||||
answering body |
|
||||||||||||||||||||||||||||||
answering dept id | 17 | ||||||||||||||||||||||||||||||
answering dept short name | Health | ||||||||||||||||||||||||||||||
answering dept sort name | Health | ||||||||||||||||||||||||||||||
hansard heading | Radioisotopes: Imports | ||||||||||||||||||||||||||||||
house id | 2 | ||||||||||||||||||||||||||||||
legislature |
|
||||||||||||||||||||||||||||||
question text | Her Majesty's Government (1) what assessment they have made of the potential impact of not reaching agreement with the EU by April 2019 on the supply of the radioisotope molybdenum-99 used to produce technetium-99m which is required for over 80 per cent of diagnostic medicine procedures in the UK; (2) what assessment they have made of the potential impact of delays or disruption to the supply of diagnostic medicine procedures that may result; and (3) what contingency plans they have put in place to mitigate such delays or disruption to that supply after Brexit. | ||||||||||||||||||||||||||||||
tabling member printed |
|
||||||||||||||||||||||||||||||
uin | HL1104 | ||||||||||||||||||||||||||||||
answer |
|
||||||||||||||||||||||||||||||
tabling member |
|